These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Cholestatic hepatitis caused by erythromycin estolate]. García Monzón C; Noguerado A; Hidalgo S; Escudero V Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470 [No Abstract] [Full Text] [Related]
3. Complete biliary obstruction due to erythromycin estolate administration in an infant. Krowchuk D; Seashore JH Pediatrics; 1979 Dec; 64(6):956-8. PubMed ID: 514726 [No Abstract] [Full Text] [Related]
4. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Keeffe EB; Reis TC; Berland JE Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110 [TBL] [Abstract][Full Text] [Related]
5. [Hepatitis caused by various derivatives of erythromycin]. Funck-Brentano C; Pessayre D; Benhamou JP Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792 [No Abstract] [Full Text] [Related]
6. Therapeutic doses of erythromycin esteolate is not cholestatic in rats in vivo. Fiebiger I; Anwer MS; Hegner D Naunyn Schmiedebergs Arch Pharmacol; 1983 May; 322(4):295-7. PubMed ID: 6866136 [TBL] [Abstract][Full Text] [Related]
7. Risk-benefit equation for erythromycin estolate. LeBel M Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788 [No Abstract] [Full Text] [Related]
8. FDA begins proceedings to remove erythromycin estolate from market. FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836 [No Abstract] [Full Text] [Related]
9. [Hepatocellular jaundice due to erythromycin estolate]. Zlotnick A Harefuah; 1978 Aug; 95(3-4):127-8. PubMed ID: 700498 [No Abstract] [Full Text] [Related]
10. Erythromycin propionate and estolate. Farre M Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648 [No Abstract] [Full Text] [Related]
11. Erythromycin jaundice: diagnosis by an in vitro challenge test. Cooksley WG; Powell LW Aust N Z J Med; 1977 Jun; 7(3):291-3. PubMed ID: 269690 [TBL] [Abstract][Full Text] [Related]
12. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Zafrani ES; Ishak KG; Rudzki C Dig Dis Sci; 1979 May; 24(5):385-96. PubMed ID: 456225 [TBL] [Abstract][Full Text] [Related]
13. Erythromycin estolate to remain on market. FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171 [No Abstract] [Full Text] [Related]